Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS
Condition:   Multidrug Resistant Tuberculosis Interventions:   Drug: Bedaquiline;   Drug: Pyrazinamide;   Drug: Linezolid;   Drug: Cycloserine;   Drug: Clofazimine Sponsor:   Huashan Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2021 Category: Research Source Type: clinical trials

Pulmonary Tuberculosis Sequelae in Patients With COPD
Conditions:   Copd;   Tuberculosis;   Quality of Life Intervention:   Other: Functional Outcome Measurements Sponsor:   Izmir Katip Celebi University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2021 Category: Research Source Type: clinical trials

Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS
Condition:   Multidrug Resistant Tuberculosis Interventions:   Drug: Bedaquiline;   Drug: Pyrazinamide;   Drug: Linezolid;   Drug: Cycloserine;   Drug: Clofazimine Sponsor:   Huashan Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2021 Category: Research Source Type: clinical trials

Pulmonary Tuberculosis Sequelae in Patients With COPD
Conditions:   Copd;   Tuberculosis;   Quality of Life Intervention:   Other: Functional Outcome Measurements Sponsor:   Izmir Katip Celebi University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2021 Category: Research Source Type: clinical trials

Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS
Condition:   Multidrug Resistant Tuberculosis Interventions:   Drug: Bedaquiline;   Drug: Pyrazinamide;   Drug: Linezolid;   Drug: Cycloserine;   Drug: Clofazimine Sponsor:   Huashan Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2021 Category: Research Source Type: clinical trials

Pulmonary Tuberculosis Sequelae in Patients With COPD
Conditions:   Copd;   Tuberculosis;   Quality of Life Intervention:   Other: Functional Outcome Measurements Sponsor:   Izmir Katip Celebi University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2021 Category: Research Source Type: clinical trials

Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS
Condition:   Multidrug Resistant Tuberculosis Interventions:   Drug: Bedaquiline;   Drug: Pyrazinamide;   Drug: Linezolid;   Drug: Cycloserine;   Drug: Clofazimine Sponsor:   Huashan Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2021 Category: Research Source Type: clinical trials

Pulmonary Tuberculosis Sequelae in Patients With COPD
Conditions:   Copd;   Tuberculosis;   Quality of Life Intervention:   Other: Functional Outcome Measurements Sponsor:   Izmir Katip Celebi University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2021 Category: Research Source Type: clinical trials

Impact of Mobile Health Interactive Software on Tuberculosis Outcomes; The Call for Life (CFLU-TB) Project
Condition:   Tuberculosis Intervention:   Other: Call for Life Uganda Sponsor:   Infectious Diseases Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 14, 2021 Category: Research Source Type: clinical trials

Treatment Success and Safety of 4 Weeks of Daily Rifapentine and Isoniazid (1HP) vs. 12 Weeks of Weekly Rifapentine and Isoniazid (3HP) for Prevention of Tuberculosis in HIV-uninfected Individuals (1v3HP for TPT in HIV-uninfected Individuals)
Condition:   Tuberculosis Interventions:   Drug: Rifapentine 600 mg and INH 300 mg;   Drug: Rifapentine 900 mg and INH 900 mg Sponsors:   Johns Hopkins University;   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 11, 2021 Category: Research Source Type: clinical trials

Pre- and Post-treatment Lung Microbiota, Metabolome and Immune Signatures at the Site of Disease in Patients With Active Pulmonary Tuberculosis
Conditions:   TB - Tuberculosis;   HIV/AIDS Intervention:   Sponsors:   University of Stellenbosch;   New York University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2021 Category: Research Source Type: clinical trials

Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide
Condition:   Tuberculosis, Pulmonary Interventions:   Drug: rifampicin;   Drug: pyrazinamide;   Drug: HRZE;   Drug: HR Sponsors:   University Hospital, Linkoeping;   Karolinska University Hospital;   Ryhov County Hospital;   Kalmar County Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2021 Category: Research Source Type: clinical trials